A novel biomarker panel examining response to gemcitabine (G) with or without erlotinib (E) for pancreatic cancer (PA) therapy in NCIC clinical trials group PA.3.

作者:Shultz David; Pal Jonathan; Graber Madeline Sydney; Heestand Gregory M; Chang Daniel Tandel; Parulekar Wendy R; Tu Dongsheng; Moore Malcolm J; Koong Albert
来源:50th Annual Meeting of the American-Society-of-Clinical-Oncology, 2014-05-30 to 2014-06-03.